TY - JOUR
T1 - Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952
AU - Bouwhuis, Marna
AU - Suciu, S
AU - Kruit, Wim
AU - Sales, F
AU - Stoitchkov, K
AU - Patel, P
AU - Cocquyt, V
AU - Thomas, J
AU - Lienard, D
AU - Eggermont, Lex
AU - Ghanem, G
PY - 2011
Y1 - 2011
N2 - S100B is a prognostic factor for melanoma as elevated levels correlate with disease progression and poor outcome. We determined its prognostic value based on updated information using serial determinations in stage IIb/III melanoma patients. 211 Patients who participated in the EORTC 18952 trial, evaluating efficacy of adjuvant intermediate doses of interferon alpha 2b (IFN) versus observation, entered a corollary study. Over a period of 36 months, 918 serum samples were collected. The Cox time-dependent model was used to assess prognostic value of the latest (most recent) S100B determination. At first measurement, 178 patients had S100B values <0.2 mu g/l and 33 >= 0.2 mu g/l. Within the first group, 61 patients had, later on, an increased value of S100B (>= 0.2 mu g/l). An initial increased value of S100B, or during follow-up, was associated with worse distant metastasis-free survival (DMFS); hazard ratio (HR) of S100B >= 0.2 versus S100B < 0.2 was 5.57 (95% confidence interval (CI) 3.81-8.16), P < 0.0001, after adjustment for stage, number of lymph nodes and sex. In stage lib patients, the HR adjusted for sex was 2.14 (95% CI 0.71, 6.42), whereas in stage III, the HR adjusted for stage, number of lymph nodes and sex was 6.76 (95% CI 4.50-10.16). Similar results were observed regarding overall survival (OS). Serial determination of S100B in stage IIb-III melanoma is a strong independent prognostic marker, even stronger compared to stage and number of positive lymph nodes. The prognostic impact of S100B >= 0.2 mu g/l more pronounced in stage III disease compared with stage IIb. (C) 2010 Elsevier Ltd. All rights reserved.
AB - S100B is a prognostic factor for melanoma as elevated levels correlate with disease progression and poor outcome. We determined its prognostic value based on updated information using serial determinations in stage IIb/III melanoma patients. 211 Patients who participated in the EORTC 18952 trial, evaluating efficacy of adjuvant intermediate doses of interferon alpha 2b (IFN) versus observation, entered a corollary study. Over a period of 36 months, 918 serum samples were collected. The Cox time-dependent model was used to assess prognostic value of the latest (most recent) S100B determination. At first measurement, 178 patients had S100B values <0.2 mu g/l and 33 >= 0.2 mu g/l. Within the first group, 61 patients had, later on, an increased value of S100B (>= 0.2 mu g/l). An initial increased value of S100B, or during follow-up, was associated with worse distant metastasis-free survival (DMFS); hazard ratio (HR) of S100B >= 0.2 versus S100B < 0.2 was 5.57 (95% confidence interval (CI) 3.81-8.16), P < 0.0001, after adjustment for stage, number of lymph nodes and sex. In stage lib patients, the HR adjusted for sex was 2.14 (95% CI 0.71, 6.42), whereas in stage III, the HR adjusted for stage, number of lymph nodes and sex was 6.76 (95% CI 4.50-10.16). Similar results were observed regarding overall survival (OS). Serial determination of S100B in stage IIb-III melanoma is a strong independent prognostic marker, even stronger compared to stage and number of positive lymph nodes. The prognostic impact of S100B >= 0.2 mu g/l more pronounced in stage III disease compared with stage IIb. (C) 2010 Elsevier Ltd. All rights reserved.
U2 - 10.1016/j.ejca.2010.10.005
DO - 10.1016/j.ejca.2010.10.005
M3 - Article
SN - 0959-8049
VL - 47
SP - 361
EP - 368
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 3
ER -